Unclassifiable Interstitial Lung Disease: Update on Challenges and Successes

Join in as faculty review the signs, symptoms, laboratory, histopathologic, and image findings that lead to better diagnosis of uILD. Review treatment strategies for managing patients with uILD and hear expert perspectives on the clinical trial findings of emerging treatments.


(1 hour program)

  • Appropriate Classification
  • Challenges With uILD Diagnosis, Prognosis, and Follow-up
  • Treatments: Evidence for and Against Corticosteroids, Immunotherapies, and Antifibrotics
  • Question and Answer Session


Date / Time
Event Details


Toby Maher, MD, PhD, FRCP

Professor of Medicine
Division of Pulmonary, Critical Care, and Sleep Medicine
University of Southern California
Director of Interstitial Lung Disease
Division of Pulmonary, Critical Care, and Sleep Medicine
Keck Medicine of USC
Los Angeles, California

Mary Beth Scholand, MD

Associate Professor and Director of the Interstitial Lung Disease Program
University of Utah
Salt Lake City, Utah

This educational activity is not certified for CME/CE credit

Goal Statement
The goal of the proposed continuing education activity is to increase knowledge and competence of pulmonologists and other healthcare professionals in identifying and treating patients with uILD.

Target Audience
This activity is primarily intended for pulmonologists and other healthcare professionals who have a role in the diagnosis and management of patients with uILD.

Learning Objectives
Upon completion of this activity, learners should be able to:

  • Identify the signs and symptoms and laboratory, histopathologic, and imaging findings that lead to a diagnosis of uILD
  • Review the evidence for success and challenges associated with available treatments that have been used to treat uILD
  • Analyze clinical trial findings on the safety and efficacy of emerging treatments in uILD


This educational activity is not certified for CME/CE credit.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.